Q-omics provides the consensus-scored FAM9C profile across patient tissues and cancer cell-line models. FAM9C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM9C is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, FAM9C RNA expression shows 8,218 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where FAM9C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM9C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM9C survival associations across molecular data types. FAM9C RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM9C RNA expression–survival associations across cancer types. High FAM9C expression shows unfavorable associations in MESO, HNSC, KIRP and ESCA, but favorable associations in SKCM and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM9C RNA expression.
This table summarizes FAM9C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM9C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM9C shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in KIRC, LIHC and STAD. The KIRC box plot shows higher FAM9C RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p < 0.001).
This table shows molecular features associated with FAM9C in patient tissues and cancer cell lines. In patient samples, FAM9C shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM9C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
